$103.86
7.277.53%
Last update: Nov 6, 5:48 PM
Spyre Therapeutics Inc (SYRE) Stock Price, Quote, News & History
SYRENASDAQ
Spyre Therapeutics shared Phase 2 SKYWAY trial data for SPY072 in rheumatoid arthritis. The therapy missed internal priority benchmarks.
You can purchase shares of Spyre Therapeutics (NASDAQ:SYRE) through any online brokerage.
Other companies in Spyre Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Spyre Therapeutics has a consensus price target of $101.00.
The stock price for Spyre Therapeutics (NASDAQ: SYRE) is $103 last updated November 6, 2026 at 5:48 PM EST.
There are no upcoming dividends for Spyre Therapeutics.
Spyre Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Spyre Therapeutics.
Spyre Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes...
